ThGM Cells in CNS Autoimmunity

中枢神经系统自身免疫中的 ThGM 细胞

基本信息

  • 批准号:
    10449359
  • 负责人:
  • 金额:
    $ 39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-12 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

SUMMARY ThGM Cells in CNS Autoimmunity ThGM cells (ThGM-CSF) are a newly described Th subset characterized by production of GM-CSF, but lacking expression of signature cytokines and master transcription factors (TF) for established Th cell lineages. In our analysis, ThGM cells were notably more abundant than Th2 and Th17 cells in the blood of healthy subjects, and even more so in MS patients. Although ThGM cells have some features of a distinct lineage, further study is needed to clarify that distinction, as well as their roles in health and disease. ThGM cells were highly encephalitogenic in the adoptive EAE model, and they can be readily found in the CNS of mice with direct EAE. Importantly, ThGM cells were enriched in the cerebrospinal fluid of MS patients, who also have greater numbers of circulating ThGM cells than healthy individuals. These findings suggest that ThGM cells contribute to the pathogenesis of CNS autoimmunity, but this subject has been only minimally studied. Over all, our data and published findings led us to hypothesize that ThGM cells play a significant pathogenic role in autoimmune neuroinflammation, MS and EAE. We will test this hypothesis in the following specific aims: Aim 1. To determine the origin of ThGM cells, and characterize the relationship between their GM-CSF expression and phenotype. Both human and mouse ThGM cells can be readily differentiated directly from naïve CD4+ T cells in vitro; however, it is unclear if ThGM cells in vivo originate from naïve precursors, or a Th lineage that switched its phenotype. We hypothesize that ThGM cells in vivo develop directly from naïve CD4+ T cells. In addition, we will study whether GM-CSF is a key determinant of ThGM cell phenotype, or these cells have a unique overall phenotype irrespective of GM-CSF expression. Aim 2. To study the role of ThGM cells in autoimmune neuroinflammation. Recent findings have suggested that ThGM cells contribute to CNS autoimmunity, as they are overrepresented in MS patients’ PBMCs, and they induce EAE in mice by passive transfer. This led us to hypothesize that ThGM cells play a significant pathogenic role in MS and EAE. In mice, we will characterize CNS autoimmunity induced by ThGM cells, while in the human system we will test their pathogenicity in organotypic brain slices, and characterize ThGM cells in MS brain lesions. Aim 3. To determine the role of candidate TFs in shaping ThGM phenotype. ThGM cells do not express master TFs of established Th lineages, suggesting that the ThGM phenotype is shaped by TF(s) differentially expressed in ThGM cells. Our findings form the basis for the hypothesis that the ThGM phenotype is directed by a set of TFs naturally overexpressed in ThGM cells compared to other Th cells. We will test this hypothesis using mice lacking candidate TFs and by knocking down expression of candidate TFs in human CD4+ T cells. Knowledge gained from these studies may modify the current concept of CNS autoimmunity.
ThGM细胞在中枢神经系统自身免疫中的作用

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Transcription Factor RUNX3 Mediates Plasticity of ThGM Cells Toward Th1 Phenotype.
  • DOI:
    10.3389/fimmu.2022.912583
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Rasouli, Javad;Casella, Giacomo;Zhang, Weifeng;Xiao, Dan;Kumar, Gaurav;Fortina, Paolo;Zhang, Guang-Xian;Ciric, Bogoljub;Rostami, Abdolmohamad
  • 通讯作者:
    Rostami, Abdolmohamad
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A.M. Rostami其他文献

A.M. Rostami的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A.M. Rostami', 18)}}的其他基金

IL-37: a novel regulator of inflammation in CNS autoimmunity
IL-37:中枢神经系统自身免疫炎症的新型调节剂
  • 批准号:
    10199564
  • 财政年份:
    2021
  • 资助金额:
    $ 39万
  • 项目类别:
ThGM Cells in CNS Autoimmunity
中枢神经系统自身免疫中的 ThGM 细胞
  • 批准号:
    10299105
  • 财政年份:
    2021
  • 资助金额:
    $ 39万
  • 项目类别:
IL-37: a novel regulator of inflammation in CNS autoimmunity
IL-37:中枢神经系统自身免疫炎症的新型调节剂
  • 批准号:
    10369694
  • 财政年份:
    2021
  • 资助金额:
    $ 39万
  • 项目类别:
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity
少突胶质细胞外囊泡:中枢神经系统自身免疫的新疗法
  • 批准号:
    10115612
  • 财政年份:
    2020
  • 资助金额:
    $ 39万
  • 项目类别:
Role of IL-7R in CNS autoimmunity
IL-7R 在中枢神经系统自身免疫中的作用
  • 批准号:
    10308115
  • 财政年份:
    2020
  • 资助金额:
    $ 39万
  • 项目类别:
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity
少突胶质细胞外囊泡:中枢神经系统自身免疫的新疗法
  • 批准号:
    10361415
  • 财政年份:
    2020
  • 资助金额:
    $ 39万
  • 项目类别:
Mechanisms of GM-CSF effect in CNS autoimmune demyelination
GM-CSF在中枢神经系统自身免疫性脱髓鞘中的作用机制
  • 批准号:
    10062792
  • 财政年份:
    2016
  • 资助金额:
    $ 39万
  • 项目类别:
The role of IL-27 in iv tolerance in EAE
IL-27 在 EAE 静脉注射耐受中的作用
  • 批准号:
    8897994
  • 财政年份:
    2014
  • 资助金额:
    $ 39万
  • 项目类别:
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis
GM-CSF 在多发性硬化症发病机制中的作用
  • 批准号:
    8767198
  • 财政年份:
    2014
  • 资助金额:
    $ 39万
  • 项目类别:
The Role of GM-CSF in the Pathogenesis of Multiple Sclerosis
GM-CSF 在多发性硬化症发病机制中的作用
  • 批准号:
    8911388
  • 财政年份:
    2014
  • 资助金额:
    $ 39万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
    Operating Grants
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了